Crucial Innovations Corp (OTC:CINV) has launched 4TP, a new patient-facing brand developed with the company's GMP-licensed cultivation and processing partners.
The brand reflects CINV's Plant-to-Patient operating model, which the company describes as a fully governed medical supply and delivery framework spanning regulated cultivation, pharmaceutical-grade processing, regulatory quality systems and clinician-led patient access.
4TP combines disciplined cultivation with structured, product-specific educational materials intended to support discussions between patients and physicians, including explanations of terpenes, cultivar characteristics and cultivation methodologies.
All 4TP cultivars are produced within SOP-driven, audited environments, with the company saying its teams prioritize terpene expression, batch consistency and documented process control from genetic selection through formulation and prescriber interface.
CINV said the launch marks a further step in its strategy to build scalable, regulator-ready medical platforms that can be replicated across jurisdictions without re-engineering core processes.